Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias

Cancer Res. 1998 Jun 15;58(12):2500-3.

Abstract

Mutation and deletion of the PTEN tumor suppressor gene occurs in about 40% of endometrial carcinomas. The purpose of this study was to determine whether PTEN mutations also are present in endometrial hyperplasias, which are premalignant precursors of invasive endometrial adenocarcinomas. Genomic DNA from 51 endometrial hyperplasias was extracted from paraffin blocks, and PCR was used to amplify the nine exons of the PTEN gene. These products were screened using single-strand conformation analysis, and variant bands were sequenced. Somatic mutations in the PTEN gene were seen in 10 of 51 cases (20%), and two mutations were found in one case. An identical 4-bp deletion in exon 8 was seen in three cases, and 8 of 11 PTEN mutations predicted truncated protein products. There was no higher frequency of PTEN mutations in endometrial hyperplasias with atypia (6 of 32; 19%) relative to those without atypia (4 of 19; 21%). These data suggest that inactivation of the PTEN tumor suppressor gene is an early event in the development of some endometrial cancers.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Endometrial Hyperplasia / genetics*
  • Endometrial Hyperplasia / pathology
  • Female
  • Genes, Tumor Suppressor / genetics*
  • Humans
  • Mutation / genetics*
  • Neoplasm Proteins / genetics*
  • PTEN Phosphohydrolase
  • Phosphoric Monoester Hydrolases*
  • Polymerase Chain Reaction
  • Protein Tyrosine Phosphatases / genetics*
  • Tumor Suppressor Proteins*

Substances

  • Neoplasm Proteins
  • Tumor Suppressor Proteins
  • Phosphoric Monoester Hydrolases
  • Protein Tyrosine Phosphatases
  • PTEN Phosphohydrolase
  • PTEN protein, human